Skip to main content
. 2022 May 4;13:885609. doi: 10.3389/fimmu.2022.885609

Table 1.

Summary of antibodies that target IL-17 pathways.

IL-17A and IL-17A/F inhibitors Secukinumab
Ixekizumab
IL-17A and IL-17F inhibitors Bimekizumab
IL-17RA inhibitors Brodalumab
IL-23 inhibitors Tildrakizumab
Risankizumab
Ustekinumab
IL-17A and TNF-α inhibitors ABT-122